Posts tagged Joseph Schwartz
Leerink ups Aurinia price target to $14

Leerink raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $14 from $10 after the company’s R&D day in New York last Friday. The stock closed at $6.15 on Oct. 20.

Read More
Leerink starts Clementia at OP

Leerink launched coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with an “outperform” rating and $23 price target. The stock closed at $16.11 on August 25.

Read More
Leerink starts CymaBay at OP

Leerink initiated coverage of CymaBay Therapeutics (NASDAQ:CBAY) with an “outperform” rating and a price target of $12. The stock closed at $6.33 on Aug. 22.

Read More
Leerink starts Arena Pharma at OP

Leerink initiated coverage of Arena Pharmaceuticals (NASDAQ:ARNA) with an “outperform” rating and $5 price target. The stock closed at $1.15 on May 18.

Read More
Leerink upgrades Achillion to OP

Leerink upgraded Achillion Pharmaceuticals (NASDAQ:ACHN) to “outperform” from “market perform” and raised its price target to $6 from $4. The stock closed at $3.78 on May 17.

Read More
Analysts raise Aurinia price targets

Analysts for H.C. Wainwright and Leerink raised their price targets for Aurinia Pharmaceuticals (NASDAQ:AUPH) after the company reviewed positive Phase 2b trial data for voclosporin in lupus nephritis (LN), which met its complete and partial remission (CR/PR) endpoints at 48 weeks.

Read More
Leerink starts Spark Therapeutics at OP

Leerink initiated coverage of Spark Therapeutics (NASDAQ:ONCE) with an “outperform” rating and $85 price target. The stock closed at $63.06 on Jan. 8.

Read More
Leerink reiterates outperform rating on Aurinia post-data

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the company reported additional positive data for its voclosporin drug candidate in patients with active lupus nephritis.

Analyst Joseph Schwartz writes that data presented today at the European Lupus Meeting showed that 70% of patients (seven-of-10) achieved complete remission (CR) at 24 weeks, compared with 57% (four-of-seven patients) reported in July.

Read More
Leerink starts Protagonist Therapeutics at outperform

Leerink Partners launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an “outperform” rating and $17 price target in 12 months. The stock closed at $12.08 on Friday.

Protagonist is aiming to become the standard of care therapy for moderate-to- severe irritable bowel disease (IBD) patients, a large and growing market opportunity.

Read More
Leerink reiterates rating on Aurinia following trial results

Leerink reiterated its “outperform” rating on Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP) after the reported top-line results with voclosporin in a Phase 2b clinical study in patients with active lupus nephritis.

Analyst Joseph Schwartz writes that the study met its primary endpoint of complete remission and improvements in partial remission versus placebo. While efficacy was higher among patients receiving the low-dose, the high-dose cohort also achieved meaningful improvements in partial remission.

Read More
Leerink downgrades Sarepta to under perform

Leerink has downgraded Sarepta Therapeutics (NASDAQ:SRPT) to “under perform” and slashed its price target to $5 from $13. The stock closed at $17.92 on Monday.

Sarpeta has been a confounding stock for which to forecast each twist and turn, but now going into the PDUFA of May 26, 2016, we believe investors have the most information yet available to ascertain investability in Sarepta,” writes analyst Joseph Schwartz.

Read More
Leerink starts Proteostasis Therapeutics at outperform

Leerink Partners has initiated coverage of Proteostasis Therapeutics (NASDAQ: PTI) with an “outperform” rating and $13 price target in 12 months. The stock closed at $5.56 on Friday.

Proteostasis’ lead candidate, PTI-428, is designed to work as an “amplifier,” which can work additively with Orkambi (corrector/potentiator combination) to increase functioning cystic fibrosis transmembrane conductance regulator (CFTR) on the cell membrane.

Read More